DPP4 and diabetes mellitus: In 2006 first DPP-4 inhibitor was familiarized, signifying that they have the potential needed to treat diabetes and imitates lesser side effects, are highly potent, long-acting, and with a bioavailability of >90% & hence oral anti-hyperglycemic inhibitors got the focus of researchers and industry to work on [6].